| Name | Title | Contact Details |
|---|
NexgenRx is a Etobicoke, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Danaher is a diversified technology leader that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers.
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.
NexMed, Inc. (NASDAQ: NEXM), due to its recent acquisition of Bio-Quant, Inc., a revenue-generating specialty contract research organization performing in vitro and in vivo pharmacology services, is now the largest specialty CRO based in San Diego, CA.
Care delivery has become dysfunctional. Its fragmented, impersonal, and expensive — but it doesnt have to be. PinpointCare is a cloud-based, flexible SaaS solution that gives healthcare professionals the power to coordinate care across the entire continuum without disrupting their workflow. Patients are engaged in creating personalized care plans and information is shared across sites of care, enabling healthcare providers to make informed decisions to better manage risk, reduce costs and improve quality.